SCHEMBL7068290

SCHEMBL7068290

CCOC(=O)Cc1nc2cc(CN3C(=O)c4ccccc4C3=O)ccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.60
MAPT P10636 5/20 0.52
HPGD P15428 2/20 0.52
HTT P42858 1/20 0.52
KMT2A Q03164 4/20 0.46
CHEK1 O14757 1/20 0.45
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
PABPC1 P11940 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
POLB P06746 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072646 0.77 KMT2A (0.55) MAPTHPGDHTTKMT2AMEN1
SCHEMBL31753163 0.77 KMT2A (0.56) HSD17B10MAPTHPGDHTTKMT2A
SCHEMBL13041542 0.76 HSD17B10 (0.60) HSD17B10MAPTHPGDCHEK1ALDH1A1
SCHEMBL3840417 0.76 HSD17B10 (0.71) HSD17B10MAPTHPGDKMT2ACHEK1
SCHEMBL31529600 0.76 HSD17B10 (1.00) HSD17B10MAPTHPGDKMT2ACHEK1
SCHEMBL1218749 0.76 HSD17B10 (1.00) HSD17B10MAPTHPGDKMT2ACHEK1
SCHEMBL7068295 0.75 HSD17B10 (0.53) HSD17B10MAPTHPGDHTTKMT2A
SCHEMBL7357580 0.74 HSD17B10 (0.67) HSD17B10MAPTHPGDKMT2ACHEK1
SCHEMBL12940747 0.74 HSD17B10 (0.67) HSD17B10MAPTCHEK1ALDH1A1SMN1; SMN2
SCHEMBL7408634 0.73 F10 (0.55) MAPTHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US disclosed
EP-1019382-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS, INC. (US) 2000-07-19 EP disclosed
WO-1998045275-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS CORPORATION (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 HSD17B10 3507/4885MAPT 2104/4885HPGD 1524/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 HSD17B10 3746/4885MAPT 2289/4885HPGD 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.